@chanelica.r's Ozempic side effects, fact-checked

What did @chanelica.r actually say?

She runs through five side effects she personally experienced on a GLP-1 medication: nausea, fatigue, diarrhea, migraines, and constipation. She's quick to add that these weren't constant, estimating "10 to 15 times" across nearly two years. Her two standout moments were a migraine that left her "in tears" on the couch, and constipation bad enough she thought she might need the ER. Her practical advice: stay on top of water, fiber, and electrolytes. She also pushes back on a warning she was given about projectile vomiting, saying it "has quite literally never happened."

This is a personal experience video, not a medical tutorial, and she frames it that way. She's not prescribing anything. She's describing what happened to her and offering two lifestyle adjustments that helped. That framing matters when evaluating it.

Does the science back this up?

Largely, yes. The side effects she lists are well-documented in clinical literature, and her frequency estimate, while unverifiable, isn't implausible for someone who has adapted over time.

The SUSTAIN trial program (Marso et al., 2016, New England Journal of Medicine) and semaglutide's FDA label both list nausea, diarrhea, vomiting, and constipation as the most common adverse events, typically front-loaded in the first weeks of treatment or after dose increases. Nausea affects roughly 20-44% of users in clinical trials, with most cases described as mild to moderate.

Migraines are trickier. Headache appears in post-marketing data and some trial subgroups, but it's not in the top-tier frequency bucket the way GI symptoms are. Dehydration from reduced appetite or GI episodes could explain migraine onset, which lines up with her electrolyte advice. Her water and fiber recommendations track with clinical guidance for managing GI symptoms on GLP-1 therapy (Davies et al., 2021, Diabetes Care).

What did they get right or wrong?

She got the core side effect profile right. Nausea, fatigue, diarrhea, and constipation are all documented. Her constipation severity is believable: GLP-1 agonists slow gastric emptying and gut motility, which can compound significantly if fluid intake is low.

The migraine claim is the weakest link, not because it's impossible, but because she presents it as a standard GLP-1 side effect without nuance. Headache is listed as a less common event, and the mechanism isn't firmly established. It's possible, but calling it a named side effect of the medication the way she implies, without noting that it could also be dehydration or another factor, is a mild overreach.

Her opening claim that she was warned "projectile vomiting" was her biggest concern is odd. Vomiting does appear in GLP-1 data, but it's not typically framed that dramatically in clinical settings. That framing sounds like informal patient counseling at best, misinformation at worst. Vomiting rates in trials are real but moderate, and most clinicians frame it as a GI risk rather than a projective event. She's right that it never happened to her, but the framing of what she was told deserves skepticism.

What should you actually know?

GLP-1 side effects are real, common, and manageable for most people, but they are not trivial. The clinical picture is more variable than any single person's experience can capture.

A few things worth knowing that this video doesn't address: side effects are dose-dependent and often worst during titration. They typically improve after weeks on a stable dose. Roughly 5-10% of people in trials discontinue due to GI intolerance (Wilding et al., 2021, New England Journal of Medicine). Severe constipation, especially with abdominal pain, can indicate ileus, a rare but serious complication that warrants immediate medical attention, not just more fiber.

Her advice on hydration and fiber is reasonable and consistent with standard guidance. But framing those as full solutions to constipation without flagging the threshold for seeking care is a gap. If you are constipated to the point of considering the ER, talk to your prescriber before it gets there, not after.